<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anorexia nervosa: Endocrine complications and their management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anorexia nervosa: Endocrine complications and their management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anorexia nervosa: Endocrine complications and their management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth A Lawson, MD, MMSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karen K Miller, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joel Yager, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 01, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H84997276">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anorexia nervosa (AN) is a disorder characterized by severe restriction of nutritional intake, despite extremely low body weight, that predominantly affects young women [
         <a href="#rid1">
          1
         </a>
         ]. In addition to restricting food intake, some women with AN binge eat and/or purge. AN is associated with significant medical complications, including endocrine dysfunction, and the highest mortality rate of any psychiatric disorder [
         <a href="#rid2">
          2
         </a>
         ]. Endocrine complications are significant and include hypothalamic-pituitary abnormalities that contribute to severe bone loss.
        </p>
        <p>
         The pathophysiology, clinical manifestations, evaluation, and management of endocrine complications in AN are reviewed here. The medical complications of AN and their management, as well as other aspects of eating disorders and their management, are found separately. (See
         <a class="medical medical_review" href="/z/d/html/14705.html" rel="external">
          "Anorexia nervosa in adults and adolescents: Medical complications and their management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2093.html" rel="external">
          "Eating disorders: Overview of epidemiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2094.html" rel="external">
          "Eating disorders: Overview of prevention and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H84997283">
         <span class="h1">
          PATHOPHYSIOLOGY OF ENDOCRINE COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anorexia nervosa (AN) is associated with multiple endocrine abnormalities, primarily in neuroendocrine axes [
         <a href="#rid3">
          3-5
         </a>
         ]. Some of the endocrine abnormalities in AN represent physiologic adaptive responses to chronic starvation and serve to shunt limited resources to the most essential physiologic processes. Others are present even after weight recovery, suggesting a potential role in disease pathophysiology or lagging recovery of endocrine dysregulation. Some contribute to the development of low bone density, one of the serious endocrine consequences of AN. In addition to bone loss, other important endocrine consequences of AN include amenorrhea (and as a result, anovulatory infertility) and hyper- or hyponatremia.
        </p>
        <p class="headingAnchor" id="H84997290">
         <span class="h2">
          Hypothalamic-pituitary abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         AN affects multiple hypothalamic-pituitary axes, which results in abnormal levels of several hormones.
        </p>
        <p class="headingAnchor" id="H691218406">
         <span class="h3">
          Reproductive
         </span>
         <span class="headingEndMark">
          —
         </span>
         Suppression of the hypothalamic-pituitary-ovarian axis results in hypogonadotropic hypogonadism with amenorrhea, estradiol deficiency, and infertility [
         <a href="#rid6">
          6
         </a>
         ]. Amenorrhea is thought to be due to the relative energy deficit associated with AN, low fat mass, and possibly changes in the hormone leptin. (See
         <a class="local">
          'Appetite-regulating hormones'
         </a>
         below.)
        </p>
        <p>
         Frequent sampling studies for gonadotropins over 24 hours in women with AN demonstrate low mean serum concentrations of luteinizing hormone (LH) with a variety of LH secretory patterns including low amplitude and an early pubertal pattern of nighttime pulses, both a reflection of impaired hypothalamic gonadotropin-releasing hormone (GnRH) secretion [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
         Low estradiol and testosterone levels may contribute to bone loss [
         <a href="#rid9">
          9-13
         </a>
         ]. Women with AN also have anovulatory infertility until their hypothalamic-pituitary-ovarian axis recovers [
         <a href="#rid6">
          6
         </a>
         ]. Reproductive function is restored in approximately 85 percent of women following weight recovery [
         <a href="#rid14">
          14
         </a>
         ], usually within six months but sometimes taking up to 18 months following weight restoration.
        </p>
        <p class="headingAnchor" id="H691219380">
         <span class="h3">
          Adrenal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased hypothalamic-pituitary-adrenal (HPA) activity in the setting of the stress of chronic starvation leads to hypercortisolemia [
         <a href="#rid15">
          15-19
         </a>
         ]. Hypercortisolemia has been linked to severity of anxiety and depressive symptoms as well as osteopenia in AN [
         <a href="#rid9">
          9,20
         </a>
         ]. There is no clinical role for evaluating these women for Cushing syndrome.
        </p>
        <p class="headingAnchor" id="H691219387">
         <span class="h3">
          Growth hormone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although growth hormone (GH) levels are high in AN, levels of the downstream hormone insulin-like growth factor-1 (IGF-1) are low, indicating a state of "resistance" to GH due to chronic starvation [
         <a href="#rid21">
          21-23
         </a>
         ]. The GH axis is an important regulator of bone formation, and dysregulation of this system contributes to AN-associated bone loss [
         <a href="#rid12">
          12,22,24,25
         </a>
         ]. There is no clinical role for measuring GH or IGF-1.
        </p>
        <p class="headingAnchor" id="H691219394">
         <span class="h3">
          Thyroid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with AN often have a "euthyroid-sick" pattern of thyroid function tests due to chronic undernutrition: triiodothyronine (T3) levels are low, and reverse T3 (rT3) levels and the ratio of thyroxine (T4) to T3 are high [
         <a href="#rid26">
          26,27
         </a>
         ]. Thyroid-stimulating hormone (TSH) and T4 levels may be normal or low [
         <a href="#rid26">
          26,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7817.html" rel="external">
          "Thyroid function in nonthyroidal illness"
         </a>
         .)
        </p>
        <p>
         These changes in thyroid hormone levels reduce the metabolic rate, leading to conservation of limited resources [
         <a href="#rid29">
          29
         </a>
         ]. When women gain weight, thyroid function returns to normal.
        </p>
        <p class="headingAnchor" id="H691219401">
         <span class="h3">
          Posterior pituitary
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secretion of
         <strong>
          vasopressin (or antidiuretic hormone [ADH])
         </strong>
         , a hormone that allows the kidney to reabsorb free water and maintain serum sodium balance, can be low or high in AN, with the associated risks of arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus) (rare) and syndrome of inappropriate antidiuretic hormone secretion (SIADH), respectively [
         <a href="#rid30">
          30
         </a>
         ]. Complications due to SIADH, such as seizures, are of particular concern since these women may have other risk factors for hyponatremia such as excessive water consumption, hypovolemia due to poor nutrition and purging behaviors, impaired renal sodium reabsorption secondary to chronic starvation, and use of psychotropic medications that result in SIADH or polydipsia [
         <a href="#rid31">
          31-33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basal levels of
         <strong>
          oxytocin
         </strong>
         , a hormone that is involved in a range of physiologic processes including social behaviors, modulation of anxiety and depressive symptoms, energy homeostasis, and bone metabolism, are decreased [
         <a href="#rid34">
          34-37
         </a>
         ]. Low nocturnal levels have been linked to severity of bone loss in AN [
         <a href="#rid35">
          35,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Abnormal oxytocin secretion following a meal is associated with the severity of disordered eating psychopathology, anxiety and depressive symptoms, and hypoactivation of regions of the brain involved in food motivation in AN [
         <a href="#rid36">
          36,39
         </a>
         ]. The finding of persistent abnormal oxytocin secretion after weight recovery suggests that this hormone may contribute to symptoms and interfere with recovery [
         <a href="#rid36">
          36,40
         </a>
         ]. Although oxytocin may play a role in the pathophysiology of AN, there is currently no clinical role for measurement of serum oxytocin concentrations.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H691219408">
         <span class="h2">
          Appetite-regulating hormones
         </span>
         <span class="headingEndMark">
          —
         </span>
         Levels of leptin, a fat-derived hormone that signals energy availability and inhibits appetite, are low in AN and return to normal when these women gain weight [
         <a href="#rid41">
          41-43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7402.html" rel="external">
          "Evaluation and management of secondary amenorrhea", section on 'Functional hypothalamic amenorrhea'
         </a>
         .)
        </p>
        <p>
         Secretion of ghrelin, a hormone released by the stomach that increases appetite, is increased in AN, as one might expect in the starved state [
         <a href="#rid44">
          44,45
         </a>
         ]. Levels of peptide YY (PYY), a hormone secreted by the gut that suppresses appetite, are high in AN and do not appear to normalize with weight recovery [
         <a href="#rid46">
          46,47
         </a>
         ]. Although leptin, ghrelin, and PYY are important regulators of appetite, there is no role for measuring levels of these hormones in the diagnosis or evaluation of patients with AN. (See
         <a class="medical medical_review" href="/z/d/html/5380.html" rel="external">
          "Ghrelin", section on 'Food intake and energy balance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2595.html" rel="external">
          "Pancreatic polypeptide, peptide YY, and neuropeptide Y", section on 'Clinical implications of the PP/PYY/NPY family of peptides'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H691220935">
         <span class="h2">
          Bone
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Females
         </strong>
         – Females with AN can experience profound bone loss and failure to accrue normal bone mass:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one study of 130 young female outpatients with AN (mean age 24 years), more than 90 percent had osteopenia and nearly 40 percent met World Health Organization (WHO) criteria for osteoporosis [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bone mineral density (BMD), geometry, and microarchitecture are impaired; bone marrow fat is increased; and estimated bone strength is diminished [
         <a href="#rid12">
          12,48-53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A two- to sevenfold increase in fractures has been reported [
         <a href="#rid54">
          54,55
         </a>
         ]. Fracture risk improves but does not normalize with recovery [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In adults, markers of bone resorption are increased, and markers of bone formation are decreased [
         <a href="#rid25">
          25
         </a>
         ]. In contrast, during adolescence, normally a time of increased bone turnover, there is a reduction of both bone resorption and formation [
         <a href="#rid22">
          22,24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The severity of bone loss in women with AN is greater than in those with normal-weight hypothalamic amenorrhea, indicating that, in addition to estradiol deficiency, there are other factors including nutritional deficiencies and hormonal abnormalities that contribute to bone loss [
         <a href="#rid10">
          10
         </a>
         ]. GH resistance, hypercortisolemia, and low testosterone have all been implicated in AN-associated osteopenia [
         <a href="#rid9">
          9,11,12,20,22,24
         </a>
         ]. In addition, abnormalities in hormones involved in appetite regulation, such as oxytocin, leptin, and PYY, may play a role in bone loss in AN, though the evidence is less clear [
         <a href="#rid12">
          12,35,38,57,58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Males
         </strong>
         – Although research on males with anorexia nervosa (AN) is limited, studies indicate that they are also at risk for bone loss [
         <a href="#rid59">
          59-63
         </a>
         ]. Similar to girls with AN, boys have reduced markers of bone turnover and BMD at the hip and spine [
         <a href="#rid61">
          61
         </a>
         ]. A cross-sectional study of 103 men, aged 18 to 63 years, with eating disorders (26 with AN) and 48 controls found that BMD Z-scores at the spine and hip were lower in individuals with AN than healthy individuals, with 65 percent of those with AN having BMD Z-scores below -2 at least one site [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H691221792">
         <span class="h2">
          Hypoglycemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dietary restriction accompanied by weight loss and excessive exercise deplete hepatic glycogen stores and disrupt hepatic gluconeogenesis. However, symptomatic hypoglycemia in ambulatory adults with AN is very rare. In severely malnourished patients, hypoglycemia can occur upon refeeding. In one study of 25 consecutive adult patients with AN (mean body mass index [BMI] 13.1 kg/m
         <sup>
          2
         </sup>
         ) admitted to a medical stabilization unit, 12 percent developed a glucose &lt;40 mg/dL upon refeeding, and severe liver function abnormalities predicted the development of hypoglycemia [
         <a href="#rid64">
          64
         </a>
         ]. There was no mention of symptomatic hypoglycemia. Nutritional rehabilitation guidelines now emphasize strategies that use &lt;40 percent of calories from carbohydrates in patients with AN to prevent development of hypoglycemia during refeeding [
         <a href="#rid65">
          65
         </a>
         ]. Other medical complications in AN are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/14705.html" rel="external">
          "Anorexia nervosa in adults and adolescents: Medical complications and their management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15777.html" rel="external">
          "Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H691219426">
         <span class="h2">
          Hypothermia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypothalamic abnormalities in thermoregulation occur in women with AN and can result in hypothermia [
         <a href="#rid66">
          66
         </a>
         ]. An outpatient study reported hypothermia in 22 percent of patients with AN [
         <a href="#rid67">
          67
         </a>
         ]. In contrast, 23 of 25 patients (92 percent) with AN admitted to a medical stabilization unit for refeeding had hypothermia [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H84997312">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H4129105124">
         <span class="h2">
          Endocrine-related features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endocrine-related features of anorexia nervosa (AN) include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reproductive dysfunction (eg, amenorrhea, loss of libido, infertility), which is common. Prior to the Diagnostic and Statistical Manual of Disorders, Fifth Edition (DSM-5), amenorrhea was a prerequisite for diagnosis. (See
         <a class="local">
          'Reproductive'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone loss (eg, stress fractures). Most women with AN have low bone mineral density (BMD) and approximately 40 percent have osteoporosis [
         <a href="#rid48">
          48
         </a>
         ]. A two- to sevenfold increase in fracture risk has been reported [
         <a href="#rid54">
          54,55
         </a>
         ]. (See
         <a class="local">
          'Bone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyponatremia (with associated nausea and headache). In a study of 215 ambulatory women with AN, 20 percent had hyponatremia [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="local">
          'Posterior pituitary'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypernatremia (increased thirst, polyuria) is rare.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical examination is generally not helpful in uncovering endocrine-related complications. Patients with lower weight and body fat are more likely to have lower leptin levels and amenorrhea.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H84997334">
         <span class="h2">
          Laboratory and imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory and imaging data may include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum sodium
         </strong>
         – Although rare, serum sodium levels may be high due to decreased vasopressin secretion. More commonly, serum sodium levels are low due to syndrome of inappropriate antidiuretic hormone (SIADH), hypovolemia, or excessive water intake. (See
         <a class="local">
          'Hypothalamic-pituitary abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroid
         </strong>
         – Thyroid function tests typically demonstrate "euthyroid-sick" syndrome (thyroid function test abnormalities associated with nonthyroidal illness). (See
         <a class="medical medical_review" href="/z/d/html/7817.html" rel="external">
          "Thyroid function in nonthyroidal illness"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone
         </strong>
         – BMD testing using dual-energy x-ray absorptiometry (DXA) typically shows low BMD. (See
         <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">
          "Screening for osteoporosis in postmenopausal women and men", section on 'Dual-energy x-ray absorptiometry'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As noted above, almost all women with AN have low bone density, and approximately 40 percent have osteoporosis at one or more sites [
         <a href="#rid48">
          48
         </a>
         ]. While all sites (spine, hip, femoral neck, and whole body) are affected in AN, the greatest decreases in bone mass and bone density are usually seen at the lumbar spine, which is primarily trabecular bone [
         <a href="#rid48">
          48,68
         </a>
         ]. (See
         <a class="local">
          'Bone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In adults with AN, a decrease in markers of bone formation and an increase in markers of bone resorption are observed [
         <a href="#rid25">
          25
         </a>
         ]. In contrast, during adolescence, normally a time of increased bone turnover, there is a reduction of both bone resorption and formation in AN [
         <a href="#rid22">
          22,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H84997341">
         <span class="h1">
          SUGGESTED EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H84997349">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         Key endocrine-related questions to ask a female presenting with anorexia nervosa (AN) address the following complications (see
         <a class="local">
          'Endocrine-related features'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reproductive dysfunction (eg, history of amenorrhea, infertility)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone loss (eg, history of low-trauma fractures; assessment of osteoporosis risk based on family history, lifestyle factors, medications, and other medical problems)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyponatremia (eg, nausea, headache; assessment of other factors related to risk of hyponatremia and complications, eg, medications, water loading, purging, seizure history)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypernatremia (increased thirst, polyuria)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H84997356">
         <span class="h2">
          Examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aside from low body weight, the physical examination is usually not helpful in terms of endocrine-related complications. (See
         <a class="local">
          'Endocrine-related features'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H84997363">
         <span class="h2">
          Biochemical and bone density testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, we suggest the following testing:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum/plasma sodium, potassium, and glucose levels in all patients
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In amenorrheic patients – Follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, prolactin (PRL), thyroid-stimulating hormone (TSH), and human chorionic gonadotropin (hCG) (to rule out causes of amenorrhea other than AN)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         25-hydroxyvitamin D (25[OH]D) level and dual-energy x-ray absorptiometry (DXA) for bone mineral density (BMD; adults at spine and hip; children at spine and whole body [less head])
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H84997370">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many of the hormonal abnormalities associated with anorexia nervosa (AN) represent adaptive responses to chronic undernutrition; following nutritional repletion, secretion of these hormones usually normalizes, but normalization may lag behind weight recovery. The following are key management issues related to endocrine complications of AN:
        </p>
        <p class="headingAnchor" id="H84997377">
         <span class="h2">
          Reproductive dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nutritional repletion is the treatment for reproductive dysfunction in AN. In most cases, menstrual cycles return and reproductive function is restored when patients gain weight [
         <a href="#rid14">
          14,69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14742.html" rel="external">
          "Anorexia nervosa in adults and adolescents: Nutritional rehabilitation (nutritional support)"
         </a>
         .)
        </p>
        <p>
         If menses do not resume with weight recovery, further evaluation for causes of amenorrhea is indicated but may not reveal an etiology, as a small percentage of patients will not resume menses even with weight recovery.
        </p>
        <p>
         Although it is possible for amenorrheic women to conceive by inducing ovulation using gonadotropins, the presence of active AN is considered to be a contraindication to ovulation induction, given the increased risk of adverse pregnancy outcomes [
         <a href="#rid70">
          70,71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7402.html" rel="external">
          "Evaluation and management of secondary amenorrhea", section on 'Initial evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H84997384">
         <span class="h2">
          "Euthyroid-sick" syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         This characteristic pattern of thyroid function tests is a physiologic adaptation to chronic starvation. Treatment with
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         is not indicated in the absence of overt hypothyroidism and could be potentially harmful given the risk for cardiac arrhythmias and bone loss in these patients. Thyroid function tests normalize when patients return to a normal weight. (See
         <a class="local">
          'Thyroid'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7817.html" rel="external">
          "Thyroid function in nonthyroidal illness"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H84997399">
         <span class="h2">
          Bone loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the profound bone loss associated with AN, measurement of bone mineral density (BMD) using dual-x-ray absorptiometry (DXA) is important. Evidence of bone loss can be useful in motivating women to recover from AN. We suggest a baseline measurement with periodic follow-up in females who are persistently low weight.
        </p>
        <p>
         Assessment of other risk factors for osteopenia, such as reproductive and family history, smoking, excessive alcohol use, and use of medications affecting bone metabolism, should be assessed. Evaluation for other contributors such as celiac disease or hyperparathyroidism, particularly in women with severe bone loss, should be considered. (See
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
         We suggest measuring a 25-hydroxyvitamin D (25[OH]D) level and encouraging adequate calcium (eg, 1200 mg) and vitamin D (eg, 800 international units) daily, from diet and supplements. Exercise regimens must be individualized. While weightbearing exercise is generally beneficial to bone, over-exercise in these women can perpetuate weight loss and amenorrhea, thereby leading to bone loss [
         <a href="#rid72">
          72
         </a>
         ]. In addition, women with severe bone loss are at risk for exercise-related stress fractures. Weight gain and restoration of menstrual cycles can independently improve BMD, and they remain the primary goal [
         <a href="#rid68">
          68,73,74
         </a>
         ].
        </p>
        <p>
         Other options for preventing and treating bone loss are limited, and there are no US Food and Drug Administration (FDA)-approved therapies.
        </p>
        <p class="headingAnchor" id="H691222612">
         <span class="h3">
          Estrogen therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-dose estrogen (oral contraceptives) has not been effective for AN-associated bone loss in adults or adolescents, but lower-dose physiologic estrogen appears more promising.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prospective trials have failed to show a benefit of combination estrogen-progestin oral contraceptives in treating AN-associated bone loss in adolescents or adults [
         <a href="#rid75">
          75-77
         </a>
         ]. Oral contraceptive pills should therefore not be prescribed for prevention of bone loss in AN.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, a trial of "physiologic" estrogen replacement in 110 adolescent girls ages 12 to 18 years with AN over 18 months resulted in improved BMD at the spine and hip [
         <a href="#rid78">
          78
         </a>
         ]. In this study, girls with a bone age ≥15 years were randomized to receive 100 mcg transdermal 17-beta-estradiol with cyclic micronized
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         , whereas immature girls with a bone age &lt;15 years were randomized to receive low incremental doses of oral ethinyl estradiol to mimic pubertal increases (3.75 mcg daily from zero to six months, 7.5 mcg daily from 7 to 12 months, 11.25 mcg daily from 13 to 18 months) versus placebo. These "physiologic" strategies for replacing estradiol resulted in BMD gains at the spine and hip compared with placebo, though the therapy did not increase BMD to normal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a second study of 23 young females with AN ages 14 to 25 years receiving transdermal 17-beta-estradiol (100 mcg daily) with cyclic micronized
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         (100 mcg daily for 10 days of every month) resulted in improvements in volumetric BMD, geometry, structure, and strength estimates at the distal radius and tibia that were similar to or exceeded changes seen in eumenorrheic, normal-weight, healthy controls. Physiologic estrogen replacement also led to greater increases in areal BMD at the lumbar spine, total hip, and whole body in comparison with the menstruating controls [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a six-month, open-label study of transdermal estradiol (0.045 mg/day) plus
         <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">
          levonorgestrel
         </a>
         (0.015 mg/day) in 11 women with AN (mean age 37 years), BMD increased at the lumbar (2.4 percent) and lateral (3.6 percent) spine [
         <a href="#rid80">
          80
         </a>
         ]. To date there are no randomized controlled trials of physiologic estrogen replacement in adult women with AN.
        </p>
        <p>
        </p>
        <p>
         In females with low BMD and sustained low weight and amenorrhea, we suggest that causes other than hypothalamic amenorrhea from AN be ruled out before estradiol/
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         therapy is considered. Once other causes of amenorrhea have been excluded, if menses have not resumed within 6 to 12 months of nutrition, psychological, and exercise modifications, we recommend short-term estrogen replacement for bone health. In women and girls with a bone age of ≥14 years, we recommend transdermal 17-beta-estradiol (100 mcg daily) with cyclic progesterone (micronized progesterone 100 to 200 mg daily for 12 days of every month). Starting with a lower dose, such as transdermal 17-beta-estradiol (50 mcg daily) with cyclic progesterone (micronized progesterone 100 mg daily for 12 days of every month), initially for a few months may reduce side effects.
        </p>
        <p>
         There are few data for girls with bone age &lt;14 years upon which to make a recommendation, but we suggest an approach similar to that for inducing puberty in girls with delayed puberty or Turner syndrome. (See
         <a class="medical medical_review" href="/z/d/html/5814.html" rel="external">
          "Approach to the patient with delayed puberty", section on 'Estradiol therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2907013401">
         <span class="h3">
          Therapies used infrequently
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bisphosphonates
         </strong>
         – Limited data suggest that bisphosphonates may be of benefit in women with AN-associated bone loss; this has not been demonstrated in adolescents, and there are safety concerns for both groups. Most importantly, bisphosphonates should not be prescribed in patients in whom pregnancy could occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A 12-month, randomized, placebo-controlled trial of
         <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">
          risedronate
         </a>
         in 77 women with AN and osteopenia or osteoporosis demonstrated improvements in BMD of 3 percent at the posterior-anterior spine, 4 percent at the lateral spine, and 2 percent at the hip compared with placebo [
         <a href="#rid81">
          81
         </a>
         ]. In contrast, transdermal testosterone replacement, which was also studied in this trial, did not improve BMD in these women.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bisphosphonates are not approved in the United States for this indication and have not been shown to be effective or safe in adolescents [
         <a href="#rid82">
          82
         </a>
         ]. In adults, bisphosphonates may be prescribed for AN-associated bone loss that is not responsive to other treatments. Rarely, bisphosphonates are used in premenopausal females with severe osteoporosis. If bisphosphonates are prescribed to females of reproductive age, a negative pregnancy test is advised prior to starting therapy, and contraception is recommended even in women with amenorrhea. (See
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis", section on 'Pharmacologic therapy for selected women'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">
          Teriparatide
         </a>
         – Although several small studies suggest that teriparatide (recombinant human parathyroid hormone) may improve BMD in adult women with AN, its role in the treatment of AN-induced bone loss is not yet clear. For women of reproductive age, teriparatide is currently only approved in the United States for treatment of bone loss from glucocorticoid use. It should not be prescribed to children or adolescents under any circumstances and should not be prescribed to patients at risk of becoming pregnant or patients at increased risk for osteosarcoma. Safety in young adults is also uncertain. Endocrine Society guidelines on management of hypothalamic amenorrhea suggest that short-term teriparatide may be used in rare cases of delayed fracture healing and very low BMD [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data in females with AN include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a randomized, placebo-controlled trial in 21 women with AN, mean age 47 years old, six months of
         <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">
          teriparatide
         </a>
         (20 mcg subcutaneously) resulted in marked increases in BMD at the posteroanterior (6 versus 0.2 percent for placebo) and lateral (10.5 versus -0.6 percent for placebo) spine [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An open-label study of
         <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">
          teriparatide
         </a>
         at the same dose for 24 months in 10 adult women with AN, ages 18 to 35 years, showed an increase in BMD at the spine (13.5 percent), femoral neck (5 percent), and total hip (4 percent) and decreased cortical bone density (2.6 percent) and thickness (6.4 percent) at the radius [
         <a href="#rid85">
          85
         </a>
         ]. Further studies involving more patients and longer follow-up will be important to determine the safety and efficacy of teriparatide for this indication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          Denosumab
         </a>
         – We do not suggest the use of denosumab in this population. In a 12-month study of women with AN randomized to denosumab (a human monoclonal antibody with antiresorptive effects on bone; 20 women receiving 60 mg subcutaneously every six months) versus placebo (10 women), denosumab reduced bone turnover markers and increased spine BMD (5.5 versus 2.2 percent for placebo) [
         <a href="#rid86">
          86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">
          "Denosumab for osteoporosis", section on 'Safety information'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H84997406">
         <span class="h2">
          Water balance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum sodium levels should be monitored, and, if abnormalities are identified, evaluation for the cause of hyper- or hyponatremia pursued. Hypernatremia is typically mild and responds to drinking free water. An appropriate history and physical examination for evaluation of hyponatremia is important as there are numerous potential causes in this population, and management of hyponatremia differs dependent on the etiology. (See
         <a class="local">
          'Posterior pituitary'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2569594059">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119119.html" rel="external">
          "Society guideline links: Eating disorders"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114189.html" rel="external">
          "Society guideline links: Amenorrhea"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H84997413">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – Anorexia nervosa (AN) is a psychiatric disorder characterized by restriction of food intake, despite extremely low weight, that predominantly affects young women. AN is associated with significant medical complications, including endocrine dysfunction, and the highest mortality rate of any psychiatric disorder. (See
         <a class="local">
          'Pathophysiology of endocrine complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endocrine manifestations
         </strong>
         – Females with AN can experience profound bone loss and failure to accrue normal bone mass. Other important endocrine consequences of AN include amenorrhea (and as a result, anovulatory infertility), hyper- or hyponatremia, and abnormal secretion of appetite-regulating peptides. (See
         <a class="local">
          'Hypothalamic-pituitary abnormalities'
         </a>
         above and
         <a class="local">
          'Appetite-regulating hormones'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         –
         <strong>
         </strong>
         Evaluation should include (see
         <a class="local">
          'Suggested evaluation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum/plasma sodium, potassium, and glucose levels in all patients
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In amenorrheic patients – Follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, prolactin (PRL), thyroid-stimulating hormone (TSH), and human chorionic gonadotropin (hCG; to rule out causes of amenorrhea other than AN)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         25-hydroxyvitamin D (25[OH]D) level and dual-energy x-ray absorptiometry (DXA) for bone mineral density (BMD)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Reproductive dysfunction
         </strong>
         – Reproductive dysfunction generally, but not always, returns to normal after weight restoration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          "Euthyroid-sick" syndrome
         </strong>
         – This is a normal adaptive response to reduce the metabolic rate and conserve resources in the setting of chronic undernutrition and should not be treated with thyroid hormone. (See
         <a class="local">
          '"Euthyroid-sick" syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Profound bone loss
         </strong>
         – Profound bone loss due to nutritional deficiencies and hormone abnormalities is common, and BMD assessment is important. Weight restoration and normalization of menstrual cycles have independent effects in improving BMD. (See
         <a class="local">
          'Bone loss'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For females with amenorrhea and low bone density, we suggest nutritional interventions weight restoration as initial therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In females whose menstrual cycles are not restored in spite of nutritional, psychological, and exercise modifications, we use physiologic estrogen rather than pharmacologic doses of estrogen (combined oral contraceptives; COCs). The approach is similar to that for women with functional hypothalamic amenorrhea. (See
         <a class="local">
          'Estrogen therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/110816.html" rel="external">
          "Functional hypothalamic amenorrhea: Evaluation and management", section on 'Estrogen replacement'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For most patients with AN and low bone density, we suggest against the use of
         <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">
          teriparatide
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, in rare cases (patients with delayed fracture healing with very low BMD), it is sometimes used.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Water balance
         </strong>
         – Serum sodium can be high or low due to abnormal vasopressin secretion and should be monitored. Other causes of hyponatremia include excessive water intake and hypovolemia due to poor nutrition and purging. (See
         <a class="local">
          'Water balance'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, 4th, American Psychiatric Association, Washington, DC 2000.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keel PK, Dorer DJ, Eddy KT, et al. Predictors of mortality in eating disorders. Arch Gen Psychiatry 2003; 60:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KK. Endocrine dysregulation in anorexia nervosa update. J Clin Endocrinol Metab 2011; 96:2939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawson EA, Klibanski A. Endocrine abnormalities in anorexia nervosa. Nat Clin Pract Endocrinol Metab 2008; 4:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhal V, Misra M, Klibanski A. Endocrinology of anorexia nervosa in young people: recent insights. Curr Opin Endocrinol Diabetes Obes 2014; 21:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyar RM, Katz J, Finkelstein JW, et al. Anorexia nervosa. Immaturity of the 24-hour luteinizing hormone secretory pattern. N Engl J Med 1974; 291:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devlin MJ, Walsh BT, Katz JL, et al. Hypothalamic-pituitary-gonadal function in anorexia nervosa and bulimia. Psychiatry Res 1989; 28:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz JL, Boyar R, Roffwarg H, et al. Weight and circadian luteinizing hormone secretory pattern in anorexia nervosa. Psychosom Med 1978; 40:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biller BM, Saxe V, Herzog DB, et al. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J Clin Endocrinol Metab 1989; 68:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grinspoon S, Miller K, Coyle C, et al. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab 1999; 84:2049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KK, Lawson EA, Mathur V, et al. Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J Clin Endocrinol Metab 2007; 92:1334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawson EA, Miller KK, Bredella MA, et al. Hormone predictors of abnormal bone microarchitecture in women with anorexia nervosa. Bone 2010; 46:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawson EA, Misra M, Meenaghan E, et al. Adrenal glucocorticoid and androgen precursor dissociation in anorexia nervosa. J Clin Endocrinol Metab 2009; 94:1367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacoangeli F, Masala S, Staar Mezzasalma F, et al. Amenorrhea after weight recover in anorexia nervosa: role of body composition and endocrine abnormalities. Eat Weight Disord 2006; 11:e20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold PW, Gwirtsman H, Avgerinos PC, et al. Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. N Engl J Med 1986; 314:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Putignano P, Dubini A, Toja P, et al. Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. Eur J Endocrinol 2001; 145:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           dos Santos E, dos Santos JE, Ribeiro RP, et al. Absence of circadian salivary cortisol rhythm in women with anorexia nervosa. J Pediatr Adolesc Gynecol 2007; 20:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hotta M, Shibasaki T, Masuda A, et al. The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. J Clin Endocrinol Metab 1986; 62:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra M, Miller KK, Almazan C, et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab 2004; 89:4972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawson EA, Donoho D, Miller KK, et al. Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. J Clin Endocrinol Metab 2009; 94:4710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Støving RK, Veldhuis JD, Flyvbjerg A, et al. Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J Clin Endocrinol Metab 1999; 84:2056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra M, Miller KK, Bjornson J, et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab 2003; 88:5615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Støving RK, Chen JW, Glintborg D, et al. Bioactive insulin-like growth factor (IGF) I and IGF-binding protein-1 in anorexia nervosa. J Clin Endocrinol Metab 2007; 92:2323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soyka LA, Misra M, Frenchman A, et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2002; 87:4177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grinspoon S, Baum H, Lee K, et al. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 1996; 81:3864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Croxson MS, Ibbertson HK. Low serum triiodothyronine (T3) and hypothyroidism in anorexia nervosa. J Clin Endocrinol Metab 1977; 44:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie RD, Isaacs AJ, Gomez J, et al. Hypothalamo-pituitary-thyroid function in anorexia nervosa: influence of weight gain. Br Med J 1978; 2:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiyohara K, Tamai H, Takaichi Y, et al. Decreased thyroidal triiodothyronine secretion in patients with anorexia nervosa: influence of weight recovery. Am J Clin Nutr 1989; 50:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onur S, Haas V, Bosy-Westphal A, et al. L-tri-iodothyronine is a major determinant of resting energy expenditure in underweight patients with anorexia nervosa and during weight gain. Eur J Endocrinol 2005; 152:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold PW, Kaye W, Robertson GL, Ebert M. Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa. N Engl J Med 1983; 308:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caregaro L, Di Pascoli L, Favaro A, et al. Sodium depletion and hemoconcentration: overlooked complications in patients with anorexia nervosa? Nutrition 2005; 21:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahia A, Chu ES, Mehler PS. Polydipsia and hyponatremia in a woman with anorexia nervosa. Int J Eat Disord 2011; 44:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evrard F, da Cunha MP, Lambert M, Devuyst O. Impaired osmoregulation in anorexia nervosa: a case-control study. Nephrol Dial Transplant 2004; 19:3034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiodera P, Volpi R, Capretti L, et al. Effect of estrogen or insulin-induced hypoglycemia on plasma oxytocin levels in bulimia and anorexia nervosa. Metabolism 1991; 40:1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawson EA, Donoho DA, Blum JI, et al. Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass. J Clin Psychiatry 2011; 72:1546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawson EA, Holsen LM, Santin M, et al. Oxytocin secretion is associated with severity of disordered eating psychopathology and insular cortex hypoactivation in anorexia nervosa. J Clin Endocrinol Metab 2012; 97:E1898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monteleone AM, Scognamiglio P, Volpe U, et al. Investigation of Oxytocin Secretion in Anorexia Nervosa and Bulimia Nervosa: Relationships to Temperament Personality Dimensions. Eur Eat Disord Rev 2016; 24:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schorr M, Marengi DA, Pulumo RL, et al. Oxytocin and Its Relationship to Body Composition, Bone Mineral Density, and Hip Geometry Across the Weight Spectrum. J Clin Endocrinol Metab 2017; 102:2814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawson EA, Holsen LM, Santin M, et al. Postprandial oxytocin secretion is associated with severity of anxiety and depressive symptoms in anorexia nervosa. J Clin Psychiatry 2013; 74:e451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afinogenova Y, Schmelkin C, Plessow F, et al. Low Fasting Oxytocin Levels Are Associated With Psychopathology in Anorexia Nervosa in Partial Recovery. J Clin Psychiatry 2016; 77:e1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grinspoon S, Gulick T, Askari H, et al. Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab 1996; 81:3861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra M, Miller KK, Kuo K, et al. Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 2005; 289:E373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gendall KA, Kaye WH, Altemus M, et al. Leptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients. Biol Psychiatry 1999; 46:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra M, Miller KK, Kuo K, et al. Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 2005; 289:E347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra M, Miller KK, Tsai P, et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2006; 91:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfluger PT, Kampe J, Castaneda TR, et al. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 2007; 92:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grinspoon S, Thomas E, Pitts S, et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med 2000; 133:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bredella MA, Misra M, Miller KK, et al. Distal radius in adolescent girls with anorexia nervosa: trabecular structure analysis with high-resolution flat-panel volume CT. Radiology 2008; 249:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bredella MA, Fazeli PK, Miller KK, et al. Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab 2009; 94:2129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh CJ, Phan CM, Misra M, et al. Women with anorexia nervosa: finite element and trabecular structure analysis by using flat-panel volume CT. Radiology 2010; 257:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachmann KN, Fazeli PK, Lawson EA, et al. Comparison of hip geometry, strength, and estimated fracture risk in women with anorexia nervosa and overweight/obese women. J Clin Endocrinol Metab 2014; 99:4664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhal V, Tulsiani S, Campoverde KJ, et al. Impaired bone strength estimates at the distal tibia and its determinants in adolescents with anorexia nervosa. Bone 2018; 106:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestergaard P, Emborg C, Støving RK, et al. Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders--a nationwide register study. Int J Eat Disord 2002; 32:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigotti NA, Neer RM, Skates SJ, et al. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA 1991; 265:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frølich J, Winkler LA, Abrahamsen B, et al. Fractures in women with eating disorders-Incidence, predictive factors, and the impact of disease remission: Cohort study with background population controls. Int J Eat Disord 2020; 53:1080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Utz AL, Lawson EA, Misra M, et al. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone 2008; 43:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KK, Grinspoon S, Gleysteen S, et al. Preservation of neuroendocrine control of reproductive function despite severe undernutrition. J Clin Endocrinol Metab 2004; 89:4434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro J, Toro J, Lazaro L, et al. Bone mineral density in male adolescents with anorexia nervosa. J Am Acad Child Adolesc Psychiatry 2002; 41:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehler PS, Sabel AL, Watson T, Andersen AE. High risk of osteoporosis in male patients with eating disorders. Int J Eat Disord 2008; 41:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra M, Katzman DK, Cord J, et al. Bone metabolism in adolescent boys with anorexia nervosa. J Clin Endocrinol Metab 2008; 93:3029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra M, Katzman DK, Clarke H, et al. Hip structural analysis in adolescent boys with anorexia nervosa and controls. J Clin Endocrinol Metab 2013; 98:2952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schorr M, Drabkin A, Rothman MS, et al. Bone mineral density and estimated hip strength in men with anorexia nervosa, atypical anorexia nervosa and avoidant/restrictive food intake disorder. Clin Endocrinol (Oxf) 2019; 90:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudiani JL, Sabel AL, Mascolo M, Mehler PS. Severe anorexia nervosa: outcomes from a medical stabilization unit. Int J Eat Disord 2012; 45:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohn MR, Madden S, Clarke SD. Refeeding in anorexia nervosa: increased safety and efficiency through understanding the pathophysiology of protein calorie malnutrition. Curr Opin Pediatr 2011; 23:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Díaz M, Becker DE. Thermoregulation: physiological and clinical considerations during sedation and general anesthesia. Anesth Prog 2010; 57:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KK, Grinspoon SK, Ciampa J, et al. Medical findings in outpatients with anorexia nervosa. Arch Intern Med 2005; 165:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KK, Lee EE, Lawson EA, et al. Determinants of skeletal loss and recovery in anorexia nervosa. J Clin Endocrinol Metab 2006; 91:2931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pitts S, Blood E, Divasta A, Gordon CM. Percentage body fat by dual-energy X-ray absorptiometry is associated with menstrual recovery in adolescents with anorexia nervosa. J Adolesc Health 2014; 54:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eagles JM, Lee AJ, Raja EA, et al. Pregnancy outcomes of women with and without a history of anorexia nervosa. Psychol Med 2012; 42:2651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bansil P, Kuklina EV, Whiteman MK, et al. Eating disorders among delivery hospitalizations: prevalence and outcomes. J Womens Health (Larchmt) 2008; 17:1523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waugh EJ, Woodside DB, Beaton DE, et al. Effects of exercise on bone mass in young women with anorexia nervosa. Med Sci Sports Exerc 2011; 43:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dominguez J, Goodman L, Sen Gupta S, et al. Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses. Am J Clin Nutr 2007; 86:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herzog W, Minne H, Deter C, et al. Outcome of bone mineral density in anorexia nervosa patients 11.7 years after first admission. J Bone Miner Res 1993; 8:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz MT, Morandé G, García-Centenera JA, et al. The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa. Eur J Endocrinol 2002; 146:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golden NH, Lanzkowsky L, Schebendach J, et al. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J Pediatr Adolesc Gynecol 2002; 15:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strokosch GR, Friedman AJ, Wu SC, Kamin M. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. J Adolesc Health 2006; 39:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra M, Katzman D, Miller KK, et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 2011; 26:2430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhal V, Nimmala S, Slattery M, et al. Physiologic Transdermal Estradiol Replacement Mimics Effects of Endogenous Estrogen on Bone Outcomes in Hypoestrogenic Women with Anorexia Nervosa. Nutrients 2022; 14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Resulaj M, Polineni S, Meenaghan E, et al. Transdermal Estrogen in Women With Anorexia Nervosa: An Exploratory Pilot Study. JBMR Plus 2020; 4:e10251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KK, Meenaghan E, Lawson EA, et al. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2011; 96:2081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golden NH, Iglesias EA, Jacobson MS, et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005; 90:3179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon CM, Ackerman KE, Berga SL, et al. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017; 102:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fazeli PK, Wang IS, Miller KK, et al. Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa. J Clin Endocrinol Metab 2014; 99:1322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milos G, Moergeli H, Sob C, et al. Positive Effect of Teriparatide on Areal Bone Mineral Density in Young Women with Anorexia Nervosa: A Pilot Study. Calcif Tissue Int 2021; 108:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haines MS, Kimball A, Meenaghan E, et al. Denosumab increases spine bone density in women with anorexia nervosa: a randomized clinical trial. Eur J Endocrinol 2022; 187:697.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 86685 Version 14.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, 4th, American Psychiatric Association, Washington, DC 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12578435" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Predictors of mortality in eating disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21976742" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Endocrine dysregulation in anorexia nervosa update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18542109" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Endocrine abnormalities in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24275621" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Endocrinology of anorexia nervosa in young people: recent insights.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4412035" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Anorexia nervosa. Immaturity of the 24-hour luteinizing hormone secretory pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2500676" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hypothalamic-pituitary-gonadal function in anorexia nervosa and bulimia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/740842" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Weight and circadian luteinizing hormone secretory pattern in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2493036" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10372709" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17284620" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19747572" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hormone predictors of abnormal bone microarchitecture in women with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19158192" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Adrenal glucocorticoid and androgen precursor dissociation in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16801735" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Amenorrhea after weight recover in anorexia nervosa: role of body composition and endocrine abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3010109" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11454512" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17289511" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Absence of circadian salivary cortisol rhythm in women with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3001125" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15472193" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19837921" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10372710" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14671143" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17389700" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Bioactive insulin-like growth factor (IGF) I and IGF-binding protein-1 in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12213868" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Abnormal bone mineral accrual in adolescent girls with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8923830" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/401822" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Low serum triiodothyronine (T3) and hypothyroidism in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/698555" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hypothalamo-pituitary-thyroid function in anorexia nervosa: influence of weight gain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2508460" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Decreased thyroidal triiodothyronine secretion in patients with anorexia nervosa: influence of weight recovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15745923" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : L-tri-iodothyronine is a major determinant of resting energy expenditure in underweight patients with anorexia nervosa and during weight gain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6835335" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15811763" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Sodium depletion and hemoconcentration: overlooked complications in patients with anorexia nervosa?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20127934" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Polydipsia and hyponatremia in a woman with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15479747" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Impaired osmoregulation in anorexia nervosa: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1943752" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effect of estrogen or insulin-induced hypoglycemia on plasma oxytocin levels in bulimia and anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21903023" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22872688" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Oxytocin secretion is associated with severity of disordered eating psychopathology and insular cortex hypoactivation in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26259495" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Investigation of Oxytocin Secretion in Anorexia Nervosa and Bulimia Nervosa: Relationships to Temperament Personality Dimensions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28586943" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Oxytocin and Its Relationship to Body Composition, Bone Mineral Density, and Hip Geometry Across the Weight Spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23759466" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Postprandial oxytocin secretion is associated with severity of anxiety and depressive symptoms in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28076675" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Low Fasting Oxytocin Levels Are Associated With Psychopathology in Anorexia Nervosa in Partial Recovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8923829" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Serum leptin levels in women with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15811876" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10418705" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Leptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11720888" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15755766" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16278259" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Elevated peptide YY levels in adolescent girls with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17119001" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11085841" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19011190" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Distal radius in adolescent girls with anorexia nervosa: trabecular structure analysis with high-resolution flat-panel volume CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19318450" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Increased bone marrow fat in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20713613" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Women with anorexia nervosa: finite element and trabecular structure analysis by using flat-panel volume CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25062461" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Comparison of hip geometry, strength, and estimated fracture risk in women with anorexia nervosa and overweight/obese women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28694162" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Impaired bone strength estimates at the distal tibia and its determinants in adolescents with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12210644" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders--a nationwide register study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1995999" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31922277" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Fractures in women with eating disorders-Incidence, predictive factors, and the impact of disease remission: Cohort study with background population controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18486583" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15356043" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Preservation of neuroendocrine control of reproductive function despite severe undernutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12014794" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Bone mineral density in male adolescents with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18528874" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : High risk of osteoporosis in male patients with eating disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18544623" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Bone metabolism in adolescent boys with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23653430" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Hip structural analysis in adolescent boys with anorexia nervosa and controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817009" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Bone mineral density and estimated hip strength in men with anorexia nervosa, atypical anorexia nervosa and avoidant/restrictive food intake disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22170021" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Severe anorexia nervosa: outcomes from a medical stabilization unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21670680" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Refeeding in anorexia nervosa: increased safety and efficiency through understanding the pathophysiology of protein calorie malnutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20331336" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Thermoregulation: physiological and clinical considerations during sedation and general anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767533" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Medical findings in outpatients with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16735492" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Determinants of skeletal loss and recovery in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24613094" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Percentage body fat by dual-energy X-ray absorptiometry is associated with menstrual recovery in adolescents with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22440333" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Pregnancy outcomes of women with and without a history of anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19006466" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Eating disorders among delivery hospitalizations: prevalence and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20962688" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Effects of exercise on bone mass in young women with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17616767" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8511987" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Outcome of bone mineral density in anorexia nervosa patients 11.7 years after first admission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11751066" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12106749" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17116511" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21698665" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35807738" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Physiologic Transdermal Estradiol Replacement Mimics Effects of Endogenous Estrogen on Bone Outcomes in Hypoestrogenic Women with Anorexia Nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31956852" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Transdermal Estrogen in Women With Anorexia Nervosa: An Exploratory Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21525157" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15784715" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28368518" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24456286" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33420643" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Positive Effect of Teriparatide on Areal Bone Mineral Density in Young Women with Anorexia Nervosa: A Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36134902" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Denosumab increases spine bone density in women with anorexia nervosa: a randomized clinical trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
